Adverse Event Profiles and Monitoring on ROS1 Inhibitors

Martin Dietrich, MD, PhD, says he manages neurologic adverse events reactively rather than proactively, because he cannot predict who will develop them and because on-target effects tend to appear early. Dietrich prefers full dose up front for central nervous system coverage before reducing to something a patient can tolerate over years, and now watches liver function, blood counts, and gastrointestinal effects more closely than neurologic ones. Wade Iams, MD, sees patients every two to three weeks for the first couple of months, counsels that fatigue tends to improve as patients acclimate to a tyrosine kinase inhibitor, and aims to reach three-month intervals with scans. Ticiana Leal, MD, says most adverse events appear early, so nursing and pharmacy teams need to know what to tell a patient who calls.